Emily McAllister suffered an extremely rare and devastating reaction, affecting roughly 1 in every 2,500. This reaction ...
The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...
As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug ...
With high temperatures and very high UV levels at the Australian Open, BBC Sport looks at the effects of playing for hours ...
Understanding the different ways wind can influence a bullet's flight is the key to placing accurate shots quickly on animals ...
PE ownership of ophthalmology practices has reshaped physician opportunities and patient care. Will things change with ...
Here are the best tool upgrades you should spend your Research Points on in Quarantine Zone: The Last Check.
Zacks Small Cap Research on MSN
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations
By Brad Sorensen, CFA NASDAQ:YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial ...
Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...
SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results